arrow
G

Gaia Griguolo

department of surgery
H指数:33
被引数:3,555

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Patterns of metastasis according to germline BRCA1/2 mutation status in patients with HER2-negative metastatic breast cancer

根据胚系BRCA1/2突变状态,HER2阴性转移性乳腺癌患者的转移模式

2026-08-170
OAAI
Long-term outcome of isolated locoregional (ILRR) breast cancer (BC) recurrence: a large retrospective Mono-institutional study

孤立性局部区域(ILRR)乳腺癌(BC)复发的长期结局:一项大型回顾性单机构研究

2026-05-010
OA
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer

BRCA突变HR阳性/HER2阴性晚期乳腺癌在接受CDK4/6抑制剂治疗后使用PARP抑制剂的实效性

2025-12-130
OAAI
Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumab

HER2阳性早期乳腺癌患者接受辅助紫杉醇和曲妥珠单抗治疗的真实世界结局

2025-11-260
OAAI
Gene expression profiling in a retrospective real-world cohort of breast cancer brain metastases and paired primary tumors identifies biological changes with potential therapeutic implications

乳腺癌脑转移瘤及其配对原发肿瘤的回顾性真实世界队列基因表达谱分析,识别出具有潜在治疗意义生物学变化

2025-07-230
PREAI
Impact of germline BRCA1/2 status on outcomes for patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a systematic review and meta-analysis

胚系BRCA1/2状态对接受CDK4/6抑制剂治疗的HR+/HER2-转移性乳腺癌患者结局的影响:一项系统评价和荟萃分析

2025-07-220
OAAI
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis

HER2DX和早期HER2阳性乳腺癌的生存结局:一项基于个体患者水平的荟萃分析

2025-07-140
PRE
Temporal evolution of breast cancer brain metastases treatments and outcomes
2025-02-200
OA
Clinical applications of radiomics and deep learning in breast and lung cancer: A narrative literature review on current evidence and future perspectives

放射组学和深度学习在乳腺癌和肺癌中的临床应用: 关于当前证据和未来前景的叙述性文献综述

2024-11-012
OAAI
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer

雌激素受体低和阴性早期乳腺癌的免疫和基因表达谱

2024-07-312
OAAI
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors

外周血淋巴细胞预测接受CDK4/6抑制剂治疗的激素受体阳性HER2-negative晚期乳腺癌患者的临床结局

2023-12-201
OAAI